2′-O-alkyl derivatives and 5′-analogues of 5-aminoimidazole-4- carboxamide-1-β-d-ribofuranoside (AICAR) as potential Hsp90 inhibitors

European Journal of Organic Chemistry

Volumn , Issue 34, 2009, Pages 5913-5919

  Bracci, Antonio ^c   Colombo, Giorgio ^b   Ronchetti, Fiamma ^a   Compostella, Federica ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Antitumor agents; Inhibitors; Metabolism; Ribonucleosides

Indexed keywords

EID: 70749125431     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200900797     Document Type: Article

References (23)

1. B. Guigas, K. Sakamoto, N. Taleux, S. M. Reyna, N. Musi, B. Viollet, L. Hue, IUBMB Life 2009, 61, 18-26.
2. A. Sriwijitkamol, N. Musi, Expert Opin. Drug Discover 2008, 3, 1167-1176.
3. C. Ségalen, S. L. Longnus, D. Baetz, L. Counillon, E. Van Obberghen, Endocrinology 2008, 149, 1490-1498.
4. N. Fujii, N. Jessen, L. J. Goodyear, Am. J. Physiol. Endocrinol. Metab. 2006, 291, E867-E8772.
5. T. R. Moopanar, X. H. Xiao, L. Jiang, Z. P. Chen, B. E. Kemp, D. G. Allen, Pflugers Arch. - Eur. J. Physiol. 2006, 453, 147-156.
6. D. R. Lara, O. P. Dall'Igna, E. S. Ghisolfi, M. G. Brunstein, Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30, 617-629.
7. R. Dixon, J. Gourzis, D. McDermott, J. Fujitaki, P. Dewland, H. Gruber, J. Clin. Pharmacol. 1991, 31, 342-347.
8. M. F. Vincent, M. D. Erion, H. E. Gruber, G. Van Den Berghe, Diabetologia 1996, 39, 1148-1155.
9. R. Rattan, S. Giri, A. K. Singh, I. Singh, J. Biol. Chem. 2005, 280, 39582-39593.
10. M. Meli, M. Pennati, M. Curto, M. G. Daidone, J. Plescia, S. Toba, D. C. Altieri, N. Zaffaroni, G. Colombo, J. Med. Chem. 2006, 49, 7721-7730.
11. L. Whitesell, S. Lindquist, Nat. Rev. Cancer 2005, 5, 761-772.
12. L. Neckers, S. P. Ivy, Curr. Opin. Oncol. 2003, 15, 419-424.
13. A different approach to compounds 2, 3, 5 and 6 has been described, see: D. T. Mangano, Methods, Compositions and Formulations for Preventing or Reducing Adverse Effects in a Patient, PTC Int. Appl., WO 2006105167, 2006.
14. a) J. P. Ferris, B. Devadas, C. H. Huang, W. Y. Ren, J. Org. Chem. 1985, 50, 747-754;
15. b) Y. Suzuki, Bull. Chem. Soc. Jpn. 1974, 47, 898-903.
16. See, for example: a) E. Casanova, A.-I. Hernández, E.-M. Priego, S. Liekens, M.-J. Camarasa, J. Balzarini, M.-J. Pérez-Pérez, J. Med. Chem. 2006, 49, 5562-5570;
17. b) M. D. Erlacher, K. Lang, B. Wotzel, R. Rieder, R. Micura, N. Polacek, J. Am. Chem. Soc. 2006, 128, 4453-4459.
18. a) L. De Napoli, A. Messere, D. Montesarchio, G. Piccialli, M. Varra, J. Chem. Soc. Perkin Trans. 1 1997, 2079-2082;
19. b) G. -Oliviero, J. Amato. N. Borbone, S. D'Errico, G. Piccialli, L. Mayol. Tetrahedron Lett. 2007, 48, 397-400.
20. N. Kohyama, Y. Yamamoto, Synthesis 2003, 2639 2642.
21. F. Liu, D. J. Austin. J. Org. Chem. 2001, 66, 8643-8645.
22. W. T. Markiewicz, J. Chem. Res. (S) 1979, 24-25.
23. G. Oliviero, J. Amato, N. Borbone, S. D'Errico, G. Piccialli, E. Bucci, V. Piccialli, L. Mayol, Tetrahedron 2008, 64, 6475-6481.